Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid TumorsSamantha Perino, Kerry A. Whalen|Molecular Cancer Therapeutics|2020Cited by 11
Abstract CT186: Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MMSagar Lonial, Jesus Bardeja, Jeffrey Matous et al.|Cancer Research|2022Cited by 11